

Treatment of Uveitis with Immunosuppressives and Biologics



Aniruddha Agarwal
M.D., Ph.D.


Conflicts of Interest: None

Six Principles of Immunosuppressive Therapies

1. **Phenotypic** presentations of uveitis
2. When and **which** IMT can I start
3. When should I **NOT** start IMT
4. I suspect **infection**, can I start IMT?
5. **Biological** therapies: when and where?
6. What **to do** when on IMT

Phenotypic Presentations of Uveitis


Acute Granulomatous Uveitis – suspect VIRAL



45-year-old lady with VA: 6/24, IOP: 42 mm Hg and
unilateral involvement

Iris Involvement in HSV




Endotheliitis +



Dawson CR, et al. Surv Ophthalmol 1976; 21:121-35.
Wensing B, et al. Ophthalmology 2011; 118:1905-10.

Intraocular TB: Clinical manifestations

1. Anterior uveitis
2. Intermediate uveitis
3. Retinal vasculitis
4. Choroiditis
 - a. Tubercles
 - b. Tubercular granuloma
 - c. Subretinal abscess
 - d. Multifocal choroiditis



When and Which IMT to Use?


Main IMTs available

- **Methotrexate: (start at 10-15 mg/week)**
 - Sarcoid and scleritis
 - Chronic anterior uveitis
 - Children with JIA
 - Avoid in young women
 - 2nd line for multifocal choroiditis/panuveitis
- **Mycophenolate mofetil (MMF) (start 500 gm/day – go up to 2 gm/day)**
 - I use it 1st/2nd line in choroiditis, VKH, chronic anterior uveitis
 - White dot syndromes

Main IMTs available

- **Azathioprine: (start at 50mg/day – go up to 150-200 mg/day)**
 - 1st/2nd line agent
 - White dot syndrome
 - Choroiditis, VKH, chronic anterior uveitis
 - Panuveitis
 - Intraocular tuberculosis
- **Cyclosporine (start 50 mg/day – go up to 100 mg/day)**
 - Patients with Behcet's disease (2nd line agent)
 - Choroiditis

Presentation
35 yo Caucasian Woman with Metamorphopsia



VA: 20/30 OD and 20/40 OS

01:00

01:45

05:12

05:00

Management Issues:





Bilateral vision threatening disease

Developed glaucoma with local therapy OU

Did not tolerate steroids at 4 weeks of initiation

Needs alternative therapy

Birdshot Chorioretinopathy



Systemic steroids initiated: Patient bridged with oral corticosteroids while MMF was initiated

Macular edema and alterations in OCT Angiography

PRACTICAL CONSIDERATIONS

Baseline

4 weeks

16 weeks

- Adequate inflammation control with IMTs
- Adequate dose optimization/ change of IMT (in case of intolerance/ suboptimal response)

Major review

Vogt-Koyanagi-Harada disease

Ghazala A. Datto O'Keefe, MD^{a,*}, Narsing A. Rao, MD^b

^aDepartment of Ophthalmology, Emory University School of Medicine, Atlanta, Georgia, USA

^bUSC Roski Eye Institute, Los Angeles, California, USA

ARTICLE INFO

Article history:

Received 5 February 2016

Received in revised form 16 May 2016

2016

Accepted 16 May 2016

Available online 27 May 2016

ABSTRACT

Vogt-Koyanagi-Harada disease, a severe bilateral granulomatous inflammation associated with serous retinal detachments, disk edema, and a sunset glow fundus, is an autoimmune inflammation that targets melanocytes in individuals susceptible to the disease. It presents clinically in 4 different phases: prodromal, uveitic, intraocular, and extraocular manifestations including headache, roaring

patients presenting weeks after initial onset of symptoms, autofluorescence shows diffuse and mottled hyperautofluorescence mixed with hypoautofluorescence in areas of exudative retinal detachments and demonstrated hypoautofluorescent dots at 6 months after treatment.¹⁰⁹ See






Fig. 9 – Widefield autofluorescence imaging demonstrating hypoautofluorescent spots in the retina.



In conditions such as VKH, delayed initiation of therapy (even weeks after initial onset) can lead to permanent damage to photoreceptors and RPE!



- a. When not to start IMT?
- b. We have an infection, can we start IMT?

2 scenarios





Large cells in AC and Vitreous in a child








Think of Retinoblastoma




Hypopyon with:



- Swollen lids, conjunctival congestion and chemosis
- Corneal edema with raised IOP
- Reduced or absent red reflex due to vitreous exudates





Differential diagnosis:

- a. *Tuberculosis*
- b. *Nocardia*
- c. Fungal(*Aspergillus*)

Cytology, PCR, Cultures

3 weeks after PPV



- a. Biologics – when and where?
- b. What to do when on IMT?

3 scenarios

Case Summary


- 11-year-old boy
- Diagnosed with JIA associated uveitis
- Also worked up for HLA B27
- Presented initially with Reiter's-like picture
- **Started on adalimumab infusions**




OS_20160921_120314_3



OS_20160921_120350_6





Outcomes



- Did well
- **Resolution of inflammation and lack of cells in the anterior chamber**
- **Adalimumab maintains ciliary body function and reduces long-term complications such as band-shaped keratopathy and hypotony**

Case Summary

43 years

Female


- **Redness, Pain and Diminution of vision OS**
- **No Trauma**
- **Diagnosed as scleritis and given short course of oral steroids**
- **Mantoux negative, ESR 82, Normal chest x-ray**



CECT Chest - Nodular lesions in RML and LLL as described with cavitation to consider possibilities of granulomatosis with polyangiitis especially with necrotizing scleritis and vitritis.






IV Rituximab: Protocol for RA




Case Summary

- A 10-year-old boy presented with diminution of vision for the past 3 months.
- He presented with hypopyon uveitis and diffuse capillaritis and disc edema on fluorescein angiography
- Mantoux: Negative
- QuantiFERON: Negative
- Initial CECT Chest: Normal
- **Was diagnosed as sarcoid and started on adalimumab**



Further Course

- He presented with fever, chest pain and slight difficulty in breathing following 6 infusions of adalimumab.
- Repeat CECT chest showed a large sub-pleural nodule




8.19mm
+0.00

0.5s/7.0mm/0.5x64



ML=-550
WW=1600
Aquilion

Axial T1
13Y/M
FC03/U03/



Key points

- Check general health each visit
- Labs – HB CBC LFT RFT
- General medical check or rheumatology assessment
- Be sure of red flags and warning signs
- Communicate!



Emirates Society of
Ophthalmology
وقرط العيون والميراث

abu dhabi
Conferences & Exhibitions Bureau

23rd EMIRATES SOCIETY OF
OPHTHALMOLOGY CONFERENCE

ESO 2026

SAVE THE DATE

17-19 APRIL 2026

HILTON ABU DHABI YAS ISLAND, UAE



eso-conferences.com

Thank you

